On the ropes, Opexa shares blast­ed by PhI­Ib mul­ti­ple scle­ro­sis tri­al flop

Opexa Ther­a­peu­tics $OPXA to­day be­comes the lat­est in a long line­up of pub­lic biotech com­pa­nies to feel the wrath of dis­ap­point­ed in­vestors in the wake of a clin­i­cal tri­al fail­ure. The biotech’s shares cratered, plung­ing 69% in pre-mar­ket trad­ing af­ter its lead ther­a­py flunked a Phase IIb for mul­ti­ple scle­ro­sis.

The news wiped out the li­on’s share of The Wood­lands, TX-based biotech’s mi­nus­cule $24 mil­lion in mar­ket cap.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER